-70%
41,99 €
Statt 139,99 €**
41,99 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar
Statt 139,99 €**
41,99 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
Als Download kaufen
Statt 139,99 €**
-70%
41,99 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar
Abo Download
9,90 € / Monat*
*Abopreis beinhaltet vier eBooks, die aus der tolino select Titelauswahl im Abo geladen werden können.

inkl. MwSt.
Sofort per Download lieferbar

Einmalig pro Kunde einen Monat kostenlos testen (danach 9,90 € pro Monat), jeden Monat 4 aus 40 Titeln wählen, monatlich kündbar.

Mehr zum tolino select eBook-Abo
Jetzt verschenken
Statt 139,99 €**
-70%
41,99 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
0 °P sammeln

  • Format: PDF


This textbook is a clear and accessible introduction to thescientific and clinical aspects of the creation, development andadministration of drugs or drug regimens used in the treatment ofcancer. Unique in its approach, this book enables the student togain an understanding of the pathological, physiological andmolecular processes governing malignancy, whilst also introducingthe role of health professionals and scientists in the research andtreatment of cancer. The book consolidates all the essentialinformation necessary for a full understanding of cancerchemotherapy, providing an informative,…mehr

Produktbeschreibung
This textbook is a clear and accessible introduction to thescientific and clinical aspects of the creation, development andadministration of drugs or drug regimens used in the treatment ofcancer. Unique in its approach, this book enables the student togain an understanding of the pathological, physiological andmolecular processes governing malignancy, whilst also introducingthe role of health professionals and scientists in the research andtreatment of cancer. The book consolidates all the essentialinformation necessary for a full understanding of cancerchemotherapy, providing an informative, inexpensive and up-to-datecoverage of the subject aimed at an undergraduate level readership. Key Features: * Incorporates numerous diagrams, tables and illustrations to aidunderstanding. * Examines key pharmacological and pharmaceutical issues such asdosing, toxicity and preparation of anti-cancer drugs. * Includes a key chapter of practice essay questions to easerevision. * Comprehensive coverage of drugs currently in pre-clinical andclinical development. * An indispensable text for undergraduate students studyingpharmacy and medicine as well as those doing courses such asmolecular biology, biomedical sciences and pharmacology which coveraspects of oncology.

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.

  • Produktdetails
  • Verlag: John Wiley & Sons
  • Seitenzahl: 342
  • Erscheinungstermin: 06.04.2009
  • Englisch
  • ISBN-13: 9780470092569
  • Artikelnr.: 37290265
Autorenporträt
Rachel Airley, School of Pharmacy and Pharmaceutical Sciences, University of Huddersfield, UK.
Inhaltsangabe
Preface

1. Cancer epidemiology

1.1 Cancer incidence, prevalence and mortality

1.2 Childhood cancers

1.3 Global epidemiology

2. Histopathology of cancer

2.1 Introduction

2.2 Malignant, benign and normal (non-malignant) tissue

2.3 Cell death

3. Carcinogenesis, malignant transformation and progression

3.1 Introduction

3.2 Chemical carcinogenesis

4. Molecular biology of cancer: Oncogenes and tumour suppressor genes

4.1 Introduction

4.2 Oncogenesis

4.3 Tumour suppressor genes

5. Tumour metastasis: A convergence of many theories

5.1 Introduction

5.2 Detachment and migration from the primary tumour

5.3 Intravasation

5.4 Transport

5.5 Extravasation

5.6 Growth of the metastatic tumour mass

6. Health professionals in the treatment of cancer

6.1 Introduction

6.2 Pathology

6.3 Radiology

6.4 Role of the surgical oncologist

6.5 Oncology pharmacy

6.6 Oncology nursing

6.7 The NHS Cancer Plan

7. Principles of cancer chemotherapy

7.1 Introduction

7.2 Timing of chemotherapy

7.3 Biomarkers and their uses

7.4 Clinical assessment of biomarkers

7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy

8. Classic anticancer agents

8.1 Introduction

8.2 Alkylating agents

8.3 Antimetabolites

8.4 Agents derived from natural or semisynthetic products

8.5 Hormonal anticancer agents

8.6 Clinically used chemotherapy regimens

9. The philosophy of cancer research

9.1 Introduction

9.2 Structure of cancer research organizations in the United Kingdom

9.3 Cancer research in the United States

10. Novel anticancer agents

10.1 Introduction

10.2 Target validation

10.3 Identification and optimization of lead drugs

10.4 Preclinical pharmacology

11. Clinical trials

11.1 Introduction

11.2 Evaluation of treatment response

11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology

12. Tumour hypoxia

12.1 Introduction

12.2 Bioreductive drugs

12.3 Inhibitors of HIF-1 and HIF-1-regulated genes

13. Antiangiogenic and antivascular agents

13.1 History of angiogenesis as a therapeutic target

13.2 Anti-angiogenic drug targets

13.3 The return of thalidomide

13.4 Monoclonal antibodies as anti-angiogenic agents

13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs

13.6 Vascular disrupting agents

14. Tyrosine kinase inhibitors

14.1 Introduction

14.2 Tyrosine kinase inhibitors targeting angiogenesis

14.3 Non-receptor tyrosine kinase inhibitors

15. Ras inhibitors

16. Inhibitors of the Akt PKB pathway

17. Targeting stress proteins: HSP90 inhibitors

18. The proteasome

18.1 Introduction

18.2 The proteasome as a target for novel drug strategies

18.3 Ubiquitylation as a target

19. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR)

19.1 Mammalian target of rapamycin

19.2 Structure and activation of mTOR

19.3 Novel anticancer agents targeting mTOR

20. Telomerase

21. Histone deacetylase: an epigenetic drug target

21.1 Introduction

21.2 HDAC and DNA packaging

21.3 HDAC inhibitors

22. Pharmaceutical problems in cancer chemotherapy

22.1 Manifestation of toxicity

22.2 Regimen-related toxicity

22.3 Secondary malignancies

22.4 Drug resistance

22.5 Pharmaceutical complications

22.6 Phlebitis and venous irritation

22.7 Health and safety

22.8 National guidance on the safe administration of intrathecal chemotherapy

23. Oncology pharmacy at home and abroad

24. Practice exam questions

25. Bibliography and further reading

Index
Rezensionen
"True to the title, the strength of the book is the discussion of chemotherapies themselves. The classical anticancer drugs are well dealt with in Chapter 8 with good background information and plenty of chemical structures and figures explaining mechanisms". (Australian Biochemist , 1 April 2011) "A useful addition to stand beside standard sources." ( Pharmaceutical Journal , December 2009)